Study design and data analysis in clinical and environmental models of nephrotoxicity
Related Experiment Video
Updated: Oct 19, 2026

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
Published on: July 17, 2016
1Centers for Disease Control and Prevention (CDC), National Center for Environmental Health, Division of Environmental Health Laboratory Sciences, Atlanta, Georgia 30341-3724, USA. pwm2@cdc.gov
Abstract:
Protocols for clinical studies of nephrotoxicity may include several elements. They include background information, study objectives, study design, data handling and analysis, organization and administration, and methods and definitions. Response variables used to indicate the development of clinically apparent renal disease should be clearly defined. Susceptibility factors such as diabetes, hypertension, cardiovascular disease, obesity, smoking history, and genetic factors may influence the development of renal disease and other health outcomes. These factors may also affect the pattern of abnormal biomarkers that appear during the development of renal disease. Some individuals who are normal by standard clinical criteria will be in various stages of disease development and will have abnormal biomarker levels. With all approaches, an adequate baseline assessment of biomarker values is critically important. Consistent findings among studies reinforce conclusions.
Related Concept Videos
Toxicokinetics: Overview
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Toxicity Testing in Animals
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
